A comparison was made of the plasma concentrations of ranitidine base in 12 normal volunteers after the administration of 100 mg intravenously and in 6 patients with terminal renal failure after 40 mg intravenously off and then during haemodialysis. The plasma ranitidine concentrations were determined by radioimmunoassay. The results suggest that reduced elimination of the drug occurs in patients with severe renal failure and that there is significant removal of the drug during haemodialysis. It is suggested that dosage reduction is advisable in patients with severe renal failure and a suitable schedule for such patients is described.
Introduction
Ranitidine is a relatively new H2-receptor antagonist which is highly water soluble with a log P value of 0 2 and pKa values of 8-2 and 2-7. A mean urinary excretion, after intravenous injection, of 68-2% as unchanged drug together with less than 10% as the Noxide, desmethyl derivative and S-oxide during the first 24 hr has been reported in normal volunteers (Carey, Martin and Owen, 1981) . The elimination half-life of ranitidine after intravenous injection ranged from 110-248 min and the mean renal clearance value was 512 ml/min in normal subjects indicating extensive tubular excretion of ranitidine in addition to glomerular filtration (Carey et al., 1981) . Reduced elimination of the drug was therefore anticipated in patients with severe renal failure.
Material and methods Subjects
Twelve normal volunteers and six patients with terminal renal failure were studied. The endogenous creatinine clearance in the 6 patients was less than 5 mi/min and all 6 were undergoing regular haemodialysis treatment using disposable Gambro Dialysers for 6-8 hr twice weekly. The normal volunteers and the patients all gave their informed consent to the study and the experimental protocol had been approved by the ethical subcommittee of Charing Cross Hospital.
Procedures
Each normal subject was given 100 mg of ranitidine base intravenously (i.v.) over I min and blood samples obtained through an indwelling i.v. needle at 1, 2, 3, 4, 5 and 12 hr.
The patients with renal failure were each studied on two separate occasions, once on a non-dialysis day and then on another occasion during haemodialysis. On each occasion, 40 mg of ranitidine base was given i.v. over I min and blood samples obtained at 1, 2, 3, 4 and 5 hr. In 4 patients during the non-dialysis study, a final blood sample was taken 24 hr after the dose. During the haemodialysis study, the 40 mg of ranitidine base was given at the start of haemodialysis.
The plasma ranitidine concentrations were determined by radioimmunoassay (Jenner et al., 1981 
